Goldman Sachs Group Inc Crispr Therapeutics Ag Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Goldman Sachs Group Inc holds 209,840 shares of CRSP stock, worth $8.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
209,840
Previous 265,347 20.92%
Holding current value
$8.54 Million
Previous $14.3 Million 31.2%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$44.62 - $62.75 $2.48 Million - $3.48 Million
-55,507 Reduced 20.92%
209,840 $9.86 Million
Q2 2024

Aug 13, 2024
BUY
$51.17 - $68.18 $6.79 Million - $9.04 Million
132,650 Added 99.96%
265,347 $14.3 Million
Q1 2024

May 15, 2024
SELL
$60.67 - $89.12 $3.33 Million - $4.89 Million
-54,923 Reduced 29.27%
132,697 $9.04 Million
Q4 2023

Feb 13, 2024
BUY
$38.62 - $72.18 $2.46 Million - $4.59 Million
63,575 Added 51.25%
187,620 $11.7 Million
Q3 2023

May 14, 2024
SELL
$45.39 - $59.0 $2.89 Million - $3.75 Million
-63,575 Reduced 33.88%
124,045 $5.63 Million
Q3 2023

Nov 14, 2023
SELL
$45.39 - $59.0 $610,041 - $792,960
-13,440 Reduced 9.78%
124,045 $5.63 Million
Q2 2023

May 14, 2024
SELL
$43.47 - $67.77 $4.35 Million - $6.77 Million
-99,969 Reduced 42.1%
137,485 $7.72 Million
Q2 2023

Aug 14, 2023
SELL
$43.47 - $67.77 $4.35 Million - $6.77 Million
-99,969 Reduced 42.1%
137,485 $7.72 Million
Q1 2023

May 14, 2024
SELL
$41.0 - $56.12 $10.7 Million - $14.6 Million
-259,779 Reduced 52.24%
237,454 $10.7 Million
Q1 2023

May 11, 2023
SELL
$41.0 - $56.12 $10.7 Million - $14.6 Million
-259,779 Reduced 52.24%
237,454 $10.7 Million
Q4 2022

May 14, 2024
SELL
$39.19 - $65.67 $9.75 Million - $16.3 Million
-248,673 Reduced 33.34%
497,233 $20.2 Million
Q4 2022

Feb 13, 2023
SELL
$39.19 - $65.67 $9.75 Million - $16.3 Million
-248,673 Reduced 33.34%
497,233 $20.2 Million
Q3 2022

May 14, 2024
BUY
$61.1 - $83.78 $15.3 Million - $21 Million
250,700 Added 50.63%
745,906 $48.7 Million
Q3 2022

Nov 10, 2022
BUY
$61.1 - $83.78 $15.3 Million - $21 Million
250,700 Added 50.63%
745,906 $48.7 Million
Q2 2022

May 14, 2024
BUY
$43.23 - $73.83 $13.3 Million - $22.7 Million
307,586 Added 163.94%
495,206 $30.1 Million
Q2 2022

Aug 15, 2022
BUY
$43.23 - $73.83 $16.4 Million - $28 Million
378,609 Added 324.72%
495,206 $30.1 Million
Q1 2022

May 16, 2022
SELL
$53.19 - $79.24 $2 Million - $2.98 Million
-37,589 Reduced 24.38%
116,597 $7.32 Million
Q4 2021

Feb 14, 2022
SELL
$70.09 - $111.29 $12.2 Million - $19.4 Million
-173,896 Reduced 53.0%
154,186 $11.7 Million
Q3 2021

Nov 10, 2021
BUY
$110.2 - $156.64 $36.2 Million - $51.4 Million
328,082 New
328,082 $36.7 Million

Others Institutions Holding CRSP

# of Institutions
490
Shares Held
58M
Call Options Held
1.1M
Put Options Held
1.9M
View Full List

About CRISPR Therapeutics AG

CRSP Quotes by TradingView
  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email